Stock Detail
AASTROM BIOSCIENCES INC
Sector: Biotechnology
Latest Quote @ Wed Jun 6 06:22:08 (15 min delayed)
| $0.4812 |
$0.5775 |
$0.5084 |
-0.0015 |
-0.29% |
|
Last Day's Data
| $0.50 |
$0.51 |
$-0.01 |
-1.96% |
0.00 |
$0.51 |
| $0.50 |
$0.49 |
222,909.00 |
23.02M |
177,688.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.52 |
0.51 |
0.50 |
0.49 |
0.48 |
Stock Profile
Aastrom Biosciences, Inc., a development stage company, develops patient-specific products for the repair or regeneration of human tissues, utilizing its proprietary adult stem cell technology. Its lead products include tissue repair cells (TRCs), which are a mixture of bone marrow-derived adult stem and progenitor cells, produced outside of the body or ‘ex vivo' from a small amount of bone marrow taken from the patient. The company also offers AastromReplicell System, a patented, integrated system of instrumentation and single-use consumable kits for the commercial production of human cells. Aastrom Biosciences is developing TRCs for the treatment of severe bone fractures, ischemic vascular disease, jaw reconstruction, and spine fusion. It also focuses on the utilization of TRCs in the areas of bone regeneration and vascular regeneration in limb ischemia resulting from diabetes and other diseases. The company has a strategic alliance with Musculoskeletal Transplant Foundation to develop and commercialize treatments for the regeneration of tissues, such as bone and cartilage. Aastrom Biosciences was incorporated in 1989 and is headquartered in Ann Arbor, Michigan.
